174 related articles for article (PubMed ID: 28164396)
1. Improved multiparametric MRI discrimination between low-risk prostate cancer and benign tissues in a small cohort of 5α-reductase inhibitor treated individuals as compared with an untreated cohort.
Starobinets O; Kurhanewicz J; Noworolski SM
NMR Biomed; 2017 May; 30(5):. PubMed ID: 28164396
[TBL] [Abstract][Full Text] [Related]
2. Characterization and stratification of prostate lesions based on comprehensive multiparametric MRI using detailed whole-mount histopathology as a reference standard.
Starobinets O; Simko JP; Kuchinsky K; Kornak J; Carroll PR; Greene KL; Kurhanewicz J; Noworolski SM
NMR Biomed; 2017 Dec; 30(12):. PubMed ID: 28961382
[TBL] [Abstract][Full Text] [Related]
3. Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.
Dutta A; Panja S; Virk RK; Kim JY; Zott R; Cremers S; Golombos DM; Liu D; Mosquera JM; Mostaghel EA; Barbieri CE; Mitrofanova A; Abate-Shen C
Eur Urol; 2017 Oct; 72(4):499-506. PubMed ID: 28385453
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Diffusion Kurtosis Imaging Versus Standard Diffusion Imaging for Detection and Grading of Peripheral Zone Prostate Cancer.
Roethke MC; Kuder TA; Kuru TH; Fenchel M; Hadaschik BA; Laun FB; Schlemmer HP; Stieltjes B
Invest Radiol; 2015 Aug; 50(8):483-9. PubMed ID: 25867657
[TBL] [Abstract][Full Text] [Related]
5. Impact of 5α-Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable Features.
Dai C; Ganesan V; Zabell J; Nyame YA; Almassi N; Greene DJ; Hettel D; Reichard C; Haywood SC; Arora H; Zampini A; Crane A; Li J; Elshafei A; Magi-Galluzzi C; Stein RJ; Fareed K; Gong M; Jones JS; Klein EA; Stephenson AJ
J Urol; 2018 Feb; 199(2):445-452. PubMed ID: 28789947
[TBL] [Abstract][Full Text] [Related]
6. Stratification of the aggressiveness of prostate cancer using pre-biopsy multiparametric MRI (mpMRI).
Dwivedi DK; Kumar R; Bora GS; Thulkar S; Sharma S; Gupta SD; Jagannathan NR
NMR Biomed; 2016 Mar; 29(3):232-8. PubMed ID: 26730884
[TBL] [Abstract][Full Text] [Related]
7. Peripheral zone prostate cancer localization by multiparametric magnetic resonance at 3 T: unbiased cancer identification by matching to histopathology.
Selnæs KM; Heerschap A; Jensen LR; Tessem MB; Schweder GJ; Goa PE; Viset T; Angelsen A; Gribbestad IS
Invest Radiol; 2012 Nov; 47(11):624-33. PubMed ID: 23011187
[TBL] [Abstract][Full Text] [Related]
8. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.
Ocak I; Bernardo M; Metzger G; Barrett T; Pinto P; Albert PS; Choyke PL
AJR Am J Roentgenol; 2007 Oct; 189(4):849. PubMed ID: 17885055
[TBL] [Abstract][Full Text] [Related]
9. Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging.
Hoeks CM; Hambrock T; Yakar D; Hulsbergen-van de Kaa CA; Feuth T; Witjes JA; Fütterer JJ; Barentsz JO
Radiology; 2013 Jan; 266(1):207-17. PubMed ID: 23143029
[TBL] [Abstract][Full Text] [Related]
10. Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors.
Shelton PQ; Ivanowicz AN; Wakeman CM; Rydberg MG; Norton J; Riggs SB; Teigland CM
Urology; 2013 May; 81(5):979-84. PubMed ID: 23523297
[TBL] [Abstract][Full Text] [Related]
11. A Single-Arm, Multicenter Validation Study of Prostate Cancer Localization and Aggressiveness With a Quantitative Multiparametric Magnetic Resonance Imaging Approach.
Maas MC; Litjens GJS; Wright AJ; Attenberger UI; Haider MA; Helbich TH; Kiefer B; Macura KJ; Margolis DJA; Padhani AR; Selnæs KM; Villeirs GM; Fütterer JJ; Scheenen TWJ
Invest Radiol; 2019 Jul; 54(7):437-447. PubMed ID: 30946180
[TBL] [Abstract][Full Text] [Related]
12. 5α-Reductase Inhibitors and Risk of Prostate Cancer Death.
Bonde Miranda T; Garmo H; Stattin P; Robinson D
J Urol; 2020 Oct; 204(4):714-719. PubMed ID: 32243243
[TBL] [Abstract][Full Text] [Related]
13. T2* relaxation time in the detection and assessment of aggressiveness of peripheral zone cancer in comparison with diffusion-weighted imaging.
Wu LM; Zhou B; Lu Q; Suo ST; Liu Q; Hu J; Haccke EM; Chen XX; Xu JR
Clin Radiol; 2016 Apr; 71(4):356-62. PubMed ID: 26823021
[TBL] [Abstract][Full Text] [Related]
14. Multiparametric magnetic resonance imaging for transition zone prostate cancer: essential findings, limitations, and future directions.
Lewis S; Besa C; Rosen A; Rastinehad AR; Semaan S; Hectors S; Taouli B
Abdom Radiol (NY); 2017 Nov; 42(11):2732-2744. PubMed ID: 28702787
[TBL] [Abstract][Full Text] [Related]
15. Use of 5α-reductase inhibitors for benign prostate hypertrophy and risk of high grade prostate cancer: a French population-based study.
Scailteux LM; Rioux-Leclercq N; Vincendeau S; Balusson F; Nowak E; Oger E;
BJU Int; 2019 Feb; 123(2):293-299. PubMed ID: 30025199
[TBL] [Abstract][Full Text] [Related]
16. Automated prostate cancer detection using T2-weighted and high-b-value diffusion-weighted magnetic resonance imaging.
Kwak JT; Xu S; Wood BJ; Turkbey B; Choyke PL; Pinto PA; Wang S; Summers RM
Med Phys; 2015 May; 42(5):2368-78. PubMed ID: 25979032
[TBL] [Abstract][Full Text] [Related]
17. Comparison of apparent diffusion coefficient calculation between two-point and multipoint B value analyses in prostate cancer and benign prostate tissue at 3 T: preliminary experience.
Park SY; Kim CK; Park BK; Kwon GY
AJR Am J Roentgenol; 2014 Sep; 203(3):W287-94. PubMed ID: 25148186
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer detection using quantitative T
Giganti F; Gambarota G; Moore CM; Robertson NL; McCartan N; Jameson C; Bott SRJ; Winkler M; Whitcher B; Castro-Santamaria R; Emberton M; Allen C; Kirkham A
J Magn Reson Imaging; 2018 Jun; 47(6):1646-1653. PubMed ID: 29135073
[TBL] [Abstract][Full Text] [Related]
19. Computer-aided diagnosis of prostate cancer in the peripheral zone using multiparametric MRI.
Niaf E; Rouvière O; Mège-Lechevallier F; Bratan F; Lartizien C
Phys Med Biol; 2012 Jun; 57(12):3833-51. PubMed ID: 22640958
[TBL] [Abstract][Full Text] [Related]
20. High and ultra-high b-value diffusion-weighted imaging in prostate cancer: a quantitative analysis.
Wetter A; Nensa F; Lipponer C; Guberina N; Olbricht T; Schenck M; Schlosser TW; Gratz M; Lauenstein TC
Acta Radiol; 2015 Aug; 56(8):1009-15. PubMed ID: 25168023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
